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Abstract
Photoacoustic imaging (PAI) is a hybrid, nonionizing modality offering excellent spatial
resolution, deep penetration, and high soft tissue contrast. In PAI, signal is generated based on the
absorption of laser-generated optical energy by endogenous tissues or exogenous contrast agents
leading to acoustic emissions detected by an ultrasound transducer. Research in this area over the
years has shown that PAI has the ability to provide both physiological and molecular imaging,
which can be viewed alone or used in a hybrid modality fashion to extend the anatomic and
hemodynamic sensitivities of clinical ultrasound. PAI may be performed using inherent contrast
afforded by light absorbing molecules such as hemoglobin, myoglobin, and melanin or exogenous
small molecule contrast agent such as near infrared dyes and porphyrins. However, this review
summarizes the potential of exogenous nanoparticle-based agents for PAI applications including
contrast based on gold particles, carbon nanotubes, and encapsulated copper compounds.
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1. Introduction
Photoacoustic (PA) imaging, also referred to as optoacoustic imaging, is an emergent hybrid
optical and ultrasound diagnostic modality with high spatial resolution and excellent soft
tissue contrast. [1–6] In a typical photoacoustic system tissue is irradiated with a
nonionizing short-pulsed laser beam within the acceptable the American National Standards
Institute (ANSI) defined limits. [3] Endogenous proteins, e,g, hemoglobin, myoglobin,
melanin, or exogenous PA contrast agents absorb the optical energy, undergo thermoelastic
expansion, and produces photoacoustic (PA) waves that are received with a clinical or non-
clinical, wide-band ultrasonic transducer (5–50 MHz). The PA images may be visualized
alone or hybridized with an interleaved ultrasound image of the same field of interest.
Because the PA image is created only from ultrasound generated within the tissue, it lacks
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the typical background speckle of ultrasound images. Moreover, PAI offers contrast
sensitivity to physiological parameters such as the concentration and oxygenation of
hemoglobin as well as unique molecular imaging contrast information.
While inherent PA contrast afforded by endogenous substances can be utilized for PA
imaging to assess levels of vascularization and oxygen saturation in tumors [1–5],
particularly malignant cancers, [7–8] a myriad of advances have been made in terms of
exogenous contrast agent development for PA molecular imaging applications, particularly
nanoparticle based technologies. As with inherent protein based contrast, the optical
absorptive of exogenous agents dictates their utility for PA imaging. Several optically active
materials have been explored as PA contrast agents, e.g. small molecule dyes, gold
nanoparticles, single walled carbon nanotubes (SWNT), copper nanoparticles etc. [2, 9–10]
However, given the optical absorptive capacity of blood and muscle, exogenous PA contrast
enhancement must significantly exceed inherent background in vivo contrast. Moreover,
these agents must have outstanding biocompatibility, appropriate in vivo stability (i.e.,
particularly during circulatory transit to targets and through the imaging period), and
desirable synthetic processing attributes, specifically tolerance to sterilization and prolonged
shelf-life stability. Although exogenous agents e.g. near infrared dye and porphyrin-based
agents, has been administered directly into the blood pool, this review will focus on
nanoparticulate compositions. (Figure 1) Examples of “nano”- contrast agents include
different classes of gold nanoparticles of varying size and morphology (spherical vs. rod,
cages); carbon nanotubes (SWNTs), hybrid nanoparticles (gold coated SWNTs) and copper
oleate encapsulated nanoparticles.
2. Nanoparticle-based contrast agents
2.1. Gold Nanoparticles
Gold nanoparticles are excitable in the near-infrared (NIR) range within the “optical
transmission window” of biological tissues (λ = 650–900 nm). This allows for deeper light
penetration, lower autofluorescence, and reduced light scattering. In addition to strong
optical absorption, gold particles, unlike small molecule fluorophores, are resistant to
photobleaching or fading due to dye destruction. [11–13] Gold nanoparticles exhibit a
phenomena known as localized surface plasmon resonance (LSPR) due to their inherent
abilities to absorb and scatter light at specific wavelengths. Nanoparticle LSPR refers to the
resonance established when incident light photons match frequency of particle surface
electrons vibrating against the opposing restoring force of positive nuclei. LSPR can be
manipulated by altering particle shape and surface coating. Several possibilities of PA
contrast imaging involving gold nanoparticles have been explored by multiple research
groups.
Gold nanocages as photoacoustic contrast agents—The LSPR of gold
nanoparticles typically must be tuned from the visible electromagnetic range of energies,
where blood and tissue attenuation impairs light penetration, into the near-infrared region
(NIR) bandwidth for maximum interrogation depth in vivo. This is the so-called NIR
window. Conventional spherical gold particles does places the LSPR in the visible light
realm, which led Younan Xia and co-workers to embark upon development of a novel class
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of nanoparticles called gold nanocages (AuNC). These particles were characterized by
hollow interiors enclosed by a singlecrystal ultrathin outer structure with porous walls. [14]
Xia demonstrated that these AuNCs exhibited wavelength plasticity and could be
manipulated to any wavelength in the NIR region based on their modifications of the
nanocage sizes and thickness. Additionally, due to their novel properties, which included
high absorption, low cytotoxicity, and their ability to be easily conjugated to tumor-specific
ligands, AuNCs provided highly effective PA contrast imaging. [15–17]
Golf nanocage synthesis: AuNCs synthesis followed a galvanic replacement reaction using
Ag solid as a template for the reduction of HAuCl4 due to their electrochemical potential
difference to form Au atoms. In this reaction, the growth of AuNCs is template over silver
nanocubes that are concurrently produced.
Ag nanocubes were synthesized using AgNO3 or CF3COOAg as a precursor to Ag, and a
polyol reduction by using ethylene glycol as a solvent and a source of reducing agent. This
reaction was further assisted with a capping agent, poly(vinyl pyrrolidone) (PVP).
Subsequently, the addition of catalytic amounts of NaHS and or Cl− ions imparted rapid
nucleation of single-crystal seeds while simultaneously, due to oxidative etching, discarded
twinned seeds, and ultimately formed single-crystal Ag nanocubes. Additional titration of
these Ag nanocubes with HAuCl4 was followed at 100°C in order to ensure maximal growth
of thin layered Au on the surface of the Ag crystals and to evade precipitation of AgCl.
Cooling the reaction precipitates AgCl, which is then dissolved in a saturated NaCl solution
and eliminated, leaving AuNCs as the final remaining product. (Figure 2) Interestingly, the
formation of AuNCs can be distinctively noted by observing the extinction spectra of the
titration of Ag nanocubes with varying volumes of HAuCl4. As more HAuCl4 is added to
the Ag nanocubes to promote epitaxial growth of AuNCs, the LSPR peak shifts from the
visible light into the NIR region.
PA imaging of cerebral cortex via AuNC: The cranium and cerebral cortex of rodent lend
themselves to photoacoustic techniques, being permeable to laser light and ultrasonic RF
waves. [18–20] Wang et al. [21] imaged of the vasculature blood pool in rat brain using gold
nanoshells with >100 nm diameters that was further improved in collaboration with Xia et
al. [22] utilizing smaller AuNCs (<50 nm). Figure 3 shows the comparative results of an ex
vivo photoacoustic study produced from pure rat blood and a mixture of AuNC-rat blood,
and an in vivo study of injections of AuNCs in the cerebral cortex of a rat model.
Reproduced with permission from (21)
Sentinel lymph node mapping via AuNCs: Sentinel lymph node (SLN) imaging is an
adjunctive technique used with minimally invasive breast cancer surgery, or lumpectory, to
guide SLN identification and resection for disease staging and prognosis. [23–28] Typically,
methylene blue dye or radioactive colloid are utilized to preoperatively localize the SLN.
However, despite its widely used practice, radioactive colloids have low precision and
difficulty in localization due to very low lateral and negligible vertical resolution, which can
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accrue to potentially harmful effects when resecting the SLN during surgical operations. On
the other hand, methylene blue stain can be difficult to place preoperatively or detect
intraoperative, offering far less sensitivity than the nuclear counterpart. Besides the
imprecision of SLN methylene blue technique, potential adverse effects including allergic
reactions are frequent with the stain. [29]
Xia and co workers demonstrated that AuNCs can be injected subcutaneously, migrate to the
draining lymphnode to afford effective sentinel lymph node mapping [30] with high spatial
resolution at imaging depths reaching 33 mm. (Figure 4)
Imaging melanoma with AuNCs: AuNCs can be surface modified with functional,
biologically relevant moieties, AuNC's surface groups were modified with thiol-PEG groups
and then conjugated to [Nle4,D-Phe7]-a-melanocyte-stimulating hormone ([Nle4,D-Phe7]-a-
MSH). [31] The homing ligand, [Nle4,D-Phe7]-a-MSH, has the ability to bind to a-MSH
receptors over-expressed on melanomas, thus acting as a method to retain and concentratie
these particles at the tumor site. Photoacoustic signals increased significantly with time as
shown in Figure 5 and 6 for the targeted [Nle4,D-Phe7]-a-MSH-AuNCs when compared
with nontargeted AuNC, resulting in almost 300% PA signal enhancement. These results
suggested that the MSH-targeted AuNCs were undergoing ligand-receptor binding with the
melanoma cells and suggested further efficacy and applicability for ligand-modified AuNCs.
2.2 Carbon nanotubes for advanced contrast agents
Because carbon nanotubes (CNT) are strongly optically active over a wide range of
wavelengths relevant to PA imaging, many studies were devoted to exploring the potential
of CNTs for PA applications. Following the work of Zharov et. al [32] who initially
demonstrated the potential of CNTs to function as exogenous PA contrast agents, others
have extended this result by coupling targeting peptides containing an RGD (arginine-
glycine-aspartate) motif to the tumor neovasculature in mice [33]. Additional modifications
of CNT chemistry and coating for enhancement of contrast [34–36] led to their use for SLN
mapping and tumor cell characterization [36–41]. Interestingly, CNTs also found utility for
therapeutic hyperthermia application, which was demonstrated in vitro with tumor and
bacterial cells [42–50].
2.3 CNT hybrids
Unfortunately, CNTs have a relatively low NIR absorption coefficient compared with gold
nanoparticles, [49] and therefore require very high local concentrations to produce useful PA
contrast imaging. [35–36] Single-walled nanotube (SWNT) have a very high surface area
(~1300 m2/g) for interacting with optical radiation. To enhance this, a hybrid gold-SWNT
was devised wherein the SWNT core coated with a gold layer (SWNT-Au) [36] (Figure 7b).
The hybrid SWNT-Au offered a more biocompatible surface that was better for chemical
bioconjugation of homing ligands or drugs. Compared with SWNT alone, the gold layer
greatly augmented LSPR the responses of the SWNT-Au hybrids.
An alternative approach to the low NIR absorption properties of SWNT was achieved by
coupling small molecule dyes onto the high surface area of the nanotubes. Liu et. al. [51]
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demonstrated this effect by loading indocyanine green (ICG) molecules onto SWNTs via
simple pi-pi bond stacking of hydrophobic benzene rings. Remarkably, hybrid ICG-SWNTs
exhibited a 20-fold increase in optical absorption (Figure 7c)
Applications of CNT geared towards photoacoustic imaging—SWNT were used
to enhance contrast from the neovasculature by coupling RGD peptides via a PL-PEG5400
[52]. Integrin-targeted SWNTs' were evaluated in mice bearing U87 gliobastoma xenograft
tumors and showed a significantly higher PA signal (~7-fold increase) in the tumor
compared to that of the untargeted SWNTs (Figure 8).
To further enhance SWNT-RGD contrast, ICG, a small molecule optical dye, was
hydrophobically coupled to the surface structure. In vitro testing of SWNT-ICG-RGD
constructs had stability in serum and a 300-fold increase in PA contrast associated with a
shift in the laser excitation wavelength from 690 nm to 780 nm when compared to SWNT-
RGD. However, despite the photoresistive nature of SWNT particles, photobleaching was
observed in the cyanine dye modified version. This optical fading of PA contrast reflected
the optical instability of ICG rather than structural degradation of the SWNT. In vivo,
SWNT-ICG-RGD were shown to target tumor neovasculature. (Figure 9) [34]
Hybrid Magnetic/Gold nanoparticles—Development of techniques to assay and
characterize circulating tumor cells (CTCs) are emerging as an area of Nanomedicine
research. Unfortunately such assays are limited by sampling errors, which relates to the
probability that adequate numbers of cancer cells are contained with the minute blood
volume measured. Typically, these methods have high sensitivities for detecting cells when
present, but limited sample volume and sparse numbers of cells circulating, particularly in
early stages of cancer, reduces the overall sensitivity of the method. One approach to
address the issue has been the development of multiplex targeting strategy utilizing a
conjugated nanoparticle consisting of a magnetic (MNP) and gold nanoparticle (GNP) which
have the properties of having an absorption spectra in the NIR region and allows for
detection of two colors at laser wavelengths of 639 and 900 nm as shown in Figure 10 A, B.
These conjugated nanoparticles were specifically synthesized to evade normal blood cells,
and to specifically target urokinase plasminogen activator (ATF) and folate receptors. [35]
PA signals indicated that the optimal NP concentration and solution volume were 109
NPs/ml for GNTs and 10–20 µl respectively. Also, there were no detectable PA signals in
mouse ear microvessels above blood background which suggested that PA signals were able
to differentiate between bound and unbound NPs, supporting its specificity. In order to
detect CTCs in a primary tumor, photoacoustic flow cytometry (PAFC) was used to measure
the progressive increase in the number of CTCs over a course of four weeks, and showed a
high correlation with respect to the progression of the tumor (Figure 10C,D). Such method
deemed as 'in vivo blood cancer test,' proves as an applicable and potential measure for early
PA diagnosis of primary tumors and prevention of metastasis.
Gold nanobeacons: Gold nanobeacons (GNB) were developed by entrapping numerous
small gold nanoparticles (spherical, 2–4 nm) within a larger colloidal particle, encapsulated
with a biocompatible phospholipids coating in our laboratories. (53–56) It was presumed
that the entrapment of numerous small gold particles would greatly amplify the signal for
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each binding event, effectively similar to a larger single gold particle, but upon particle
metabolism, the gold particles, falling below the renal elimination threshold (6–10 nm),
would be bioeliminated through the kidney and urine. Moreover, the interaction of the small
particles within the matrix of the lipid encapsulated particle would lead to effectively
creating a randomly irregular shapes that would shift the optical absorbance peak for visible
into the NIR spectral region for optimal in vivo use.
The first generation gold nanobeacon (GNB1) were synthesized by suspending octylthiol-
coated spherical gold nanoparticles (AuNPs, 2 w/v%,) in vegetable oil (20 vol%) matrix
followed by homogenization of the mixture with phospholipid surfactants mixture (2 w/v%)
(Figure 11). The phospholipids mixture was comprised of phosphatidylcholine (PC, 91 mole
%) and cholesterol (8 mole %) and included biotin-caproyl-PE (1 mole %) or a phospholipid
anchored homing ligand (0.3 to 1.0 mole %) at the equimolar expense of PC dependent on
the biological target under question. The GNB1 particles were 154 ± 10 nm with
polydispersity and zeta potential of 0.08 ± 0.03 and −47 ± 7 mV, respectively (Brookhaven
Instrument Co.). Gold content, determined by ICP-MS, was 1080 µg/g of the 20% colloid
suspension. UV-vis spectroscopy confirmed the absorbance at ~520 nm and in the near-
infrared (NIR) window (~900 nm). GNB1 particles exhibited remarkable stability as
observed by the particle size and zeta potential, which varied <5% over 100 days when
stored at 4°C under argon in sealed serum vials.
The PA signal from a 20% GNB suspension mixed 1:1 with rat blood within Tygon® tubing
(I.D. 250 µm, O.D. 500 µm) was 15 times stronger than that from pure rat blood. [14] When
monitored over the entire 740–820 nm NIR window, the average PA signal enhancement by
GNB over blood was greater than 10-fold. (Figure 12) While the agent offered high contrast
for typical blood pool applications, the intent of the agent was for vascular-targeted
molecular imaging medical applications of clinical importance and unmet need, such as
intravascular thrombosis, neovascularization in cancer and atherosclerosis, and
inflammation in cancer, arthritis, and more. Detecting intravascular targets requires a
substantial signal over the background contrast associated with circulating erythrocyte
hemoglobin.
The initial target for GNB1 was to detect fibrin in thrombosis as a means to diagnose
ruptured carotid atherosclerotic plaques in patients at high risk for stroke. Today, ultrasound
is used to assess carotid stenosis as clinical tool to guide medical decisions for surgical
carotid endarterectomy (CEA) versus medical therapy alone. While patients with greater
than 70% stenosis benefit from CEA, the vast majority of high risk individuals stroking over
a two year period have less than 60% stenosis. In many patients with severe disease, small
and repeated microruptures of the plaque intima with intermittent healing preceeds a major
event. To minimize the financial and human costs of stroke, PA imaging could be added to
standard diagnostic carotid imaging of high-risk patients as a technique to identify
microthrombi in small endothelial microfissures, which could potentially support earlier
surgical intervention and a greater reduction in stroke incidence.
As an initial proof of concept, GNB1 and the control nanobeacons (i.e., containing no gold)
were pretargeted to acellular fibrin clot phantoms with classic avidin-biotin coupling. The
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particles were homed to fibrin using a well-characterized biotinylated anti-human fibrin-
specific monoclonal antibody (NIB5F3). [57] The clots were prepared in low-density
polyethylene (LDPE) tube (~1 cc volume, I. D. ~6 mm) and treated with biotinylated GNB
and control (targeted, no gold nanobeacon). Figures 12(E) and 12(F) show cross-sectional
PAT images using a curved array PAT system [58] with an 800 nm wavelength laser. As
evident from the images, high contrast was clearly appreciated for the clots targeted with
biotinylated GNB1 in comparison to the control clot.
The cross-sectional PAT images were obtained using a PA breast scanner system, [59] of the
same control and targeted plasma clots, respectively [Figures 12(G) and 12(H)]. [53] Similar
to the previous experiments, the targeted plasma clot was clearly distinguishable (Figure
12(F)) in the PAT image, whereas the control clot image was not appreciable (Figure 12(E)).
This result was corroborated analytically by total gold content analyses using inductively
couple plasmon resonance (ICP-MS). The total gold content of the clots with targeted
GNB1, nontargeted GNB1 and targeted nonmetallic nanobeacons were found to be 47µg/g,
not detected (ND, <0.02 µg/g) and ND respectively, by ICP-MS. This experiment, for the
first time, clearly illustrated the concept of intravascular PA with GNB1.
Gold nanobeacons (Rod) as alternative to spherical nanoparticles: Gold’s optical
properties can further be tuned and optimized to have more near infrared absorption. Rod-
shaped gold nanoparticles (i.e., nanorods) offer distinct optical properties resulting from two
surface plasmon (SP) bands corresponding to the transverse and longitudinal SP bands in the
visible (λ = 520 nm) and the NIR (λ = 900 nm) regions, respectively. [11–13] Gold nanorods
are frequently used as probes for fluorescence, light scattering, and two-photon
luminescence imaging due to a large intrinsic extinction coefficient of the longitudinal band.
The longitudinal SP bands are very sensitive to the aggregation of gold nanorods and the
peak points of the SP bands predominantly depend on the anisotropic shape of each gold
nanorod. The aggregation of rods generates isotropic (random) coupling of SP oscillations,
and produces dramatic changes of the longitudinal SP bands. With these unique properties,
gold nanorods interacting as a random cluster within a phospholipid encapsulated
nanoparticle were expected to provide excellent contrast for photoacoustic imaging in the
near-IR region.
The self-assembled gold nanobeacons (rods) [GNBR] was based on the selfassembly of
phospholipids in aqueous media to entrap multiple copies (i.e. hundreds) of gold atoms. [55]
Parent gold nanorods (polymer coated GNR; transmission electron microscope axial
diameter: 25 ± 5 nm, length: 80 ± 8 nm; lLSPR: 750nm, lTSPR: 530 nm) (Fig 13A) were
dispersed in chloroform and premixed with vegetable oil (20% v/v almond oil) core matrix
before encapsulated within phospholipids coating.
This synthesis resulted in an encapsulation of ~127 gold metal atoms (ICP-MS = 8.12 µg of
gold/g of 20% colloidal nanobeacon), markedly less than GNB1. The GNBR particles had
nominal hydrodynamic diameter of 129 ± 7 nm as measured by dynamic light scattering
(DLS). The polydispersity and zeta potential were measured as 0.06 ± 0.02 and −41 ± 12
mV (Brookhaven Instrument Co.), respectively. The large negative zeta potential implied
successful phospholipids encapsulation and high colloidal stability of these nanoparticles.
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The dehydrated state diameter (Dav) and height parameters (Hav) of the GNBR were 105 ±
28 and 60 ± 24 nm, as measured by transmission electron microscopy (TEM) and atomic
force microscopy measurements (AFM), respectively (Figure 13B and 13C). Contrary to
GNB1 the encapsulation efficiency of the gold nanorods was low per GNBR, which was
anticipated due to the larger and irregular shape of the gold nanorods. Ultimately, GNBR had
less PA contrast relative to blood pool contrast (approximately 3-fold) and the larger gold
nanorod size exceeded the renal threshold for bioelimination, bringing the issue of long-term
safety in patients who would receive and likely retain these rods for life through out their
bodies. With these results and concerns, subsequent studies from the group mainly utilized
spherical gold nanoparticles similar to GNB1.
Sentinel Lymphnode Imaging: As mentioned previously, breast cancer patients often
undergo sentinel lymphnode biopsy (SLNB) in lieu of radical axillary dissection to exclude
metastatic disease in patients undergoing lumpectomy. However, the technique can be
complicated and the recovery of lymph nodes (LNs) is less adequate than expected and often
the key tissue is missed. [60–61] Moreover, SLNB has been associated with post biopsy
complications e.g. local seroma formation, lymphedema, nerve injury and numbness of
arms. [62] In this context, efforts to improve noninvasive imaging of the axillary
lymphnodes to guide minimally invasive percutaneous fineneedle biopsy (FNAB) or
selective node resection for staging for breast cancer patients remains clinically relevant.
Photoacoustics imaging offers marked advancements over typical preoperative methylene
blue dye or radioactive labeling techniques to enhance intraoperative localization and
resection. Contrast agents injected subcutaneously will migrate into lymphatics and travel to
the sentinel LNs and can be detected at depths of 4 to 5 cm with PA imaging. In a series of
studies, Pan et. al. demonstrated that the lymphatic transport of the nanopartculate contrast
agents was highly influenced by size and mass.
The effectiveness of GNB1 distribution into sentinel lymph node was studied first following
a subcutaneous forepaw injection in a rodent model. [54] A sagittal maximum amplitude
projection (MAP) photoacoustic image of the axillary area clearly delineated the vasculature
by virtue of the light absorbing red blood cells with high spatial resolution of ~500 µm.
Within 5 min, GNB1 was found accumulated in the SLN and in adjacent secondary LN in
the same chain. The signal clearly highlighted the lymphnode at this shallow depth,
however, inorder to achieve a more robust contrast particularly for nodes farther from the
transducer, further formulation approaches were considered and studied.
The most common, ´bigger is better´ mentality led to the development and evaluation of a
larger PA agent with substantially more gold per particle than GNB1. In this approach, GNB
was a polymer encapsulated gold nanobeacon (GNBP). In a typical synthesis of GNBP, a di-
block co polymer (polystyrene-b-polyacrylic acid) PS-b-PAA [63–66] (Mn×103: 0.8-b-29.3
PDI=1.18, 0.0033 mmoles) was dissolved in a mixture of methanol and CHCl3 (4:1) and
subjected to controlled evaporation under reduced pressure to generate a thin film of
polymer. The thin film was dispersed in deionized water (0.2 µM) by probe sonication at
ambient temperature. Octanethiol coated AuNPs (2w/v%) were suspended in polysorbate
(sorbitan monolaureate (5 vol%) and microfluidized with PS-b-PAA dispersion (0.5 vol%)
yielding a 10% colloidal suspension of nanoparticles (Figure 14). The nanobeacons were
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purified by exhaustive dialysis against infinite sink of nanopure water using cellulosic
dialysis membrane (20 kDa MWCO). GNBP (289 ± 24 nm) had a narrow distribution
(polydispersity index: 0.15 ± 0.04). Following this approach, the gold content of GNB1
(6120 metal atoms/particle) was impressively enhanced to reach 71,493 gold metal atoms
per GNBP. As expected, GNBP produced very strong PA signal, which was significantly
higher than GNB1. [54]
However, contrary to our expectations, GNBP was unable to provide signal enhancement in
vivo. Injection of GNBP into the rat forepaw followed by serial examination of the draining
lymphnodes with PA imaging demonstrated no detectable signal over the anticipated course
of the imaging session (Figure 6D). The LN territories of the animals were reimaged daily
for the the next 3 days with no significant migration to and uptake of GNBP by the sentinel
lymphnode. Despite a tenfold increase in gold content and ultrahigh PA signal contrast in
vitro, GNBP was ineffective for in vivo LN imaging. We hypothesized that the larger size
(and or mass) of GNBP led to poor migration of the particles to and within the lymphatic
channels, essentially leaving the contrast agents essentially at the injection site. Since bigger
particles with more gold was ineffective, we explored the potential that a smaller particle
with less gold, smaller size, and less mass would have better lymphatic migration. A third
smaller gold nanobeacon (GNBS), was produced and examined. [54]
GNBS was prepared similar as GNB1 by retuning the core matrix to polysorbates (Figure
14). Briefly, oleate-coated AuNPs (2 w/v% of inner matrix, 2–4 nm) were suspended in
polysorbate (sorbitan monolaureate, 20 vol%) and homogenized with a surfactant mixture,
resuspended from a lipid film, at 137.9 MPa (i.e., 20,000 PSI) for 4 min. The surfactant
mixture was mainly comprised of phosphatidylcholine (PC) (92 mol% of lipid constitutents)
and cholesterol (8 mole %). Hydrodynamic particle size for GNBS was 92 ± 12 nm with a
polydispersity index of 0.35 ± 0.05. The zeta potential (ζ) was −35 ± 8 nm, confirming
appropriate particle encapsulation. Gold metal atom (9 gold metal atoms per GNBS) content
per particle was determined to be much less in comparison to GNB1 and GNBP. The result
with GNBS was dramatically improved relative to GNB1 and GNBp.
In the rat sentinel lymph node model, the blood-filled microvasculature was clearly visible
(marked with red arrows) while the lymph node, devoid of optical absorbers, was not seen at
baseline as before. Figure 6F and 6G present two MAP images of the same axillary area 5
min and 20 min after GNB-S subcutaneous injection into the mouse forepaw, respectively.
The SLN is dramatically apparent as a bright spot (green arrow) and the conspicuity of the
lymph node far exceeds what achieved previously with GNB1 or GNBp. GNBS flowing
within the lymphatic vessel toward and into the sentinal lymphnode was observed at 5 min
post injection. Within 10 mins post GNBS injection, the nanobeacons completed migration
into LN and a persistent and robust signal was appreciated over the next hour. The contrast
of the sentinel LN to the surrounding blood vessel was calculated to be 9:1 (ratio of the
peak-to-peak PA signal amplitude obtained from blood vessel and SLN) after GNBS
injection. [54] In summary, the smaller GNBS, with less gold particles per nanoparticle, less
mass, and smaller size were more effective in detecting the SLN in comparison to the larger
GNB particles. Moreover, the particles were retained adequately in the LN for practical use.
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Integrin-specific photoacoustic imaging of angiogenesis: Angiogenesis is an essential
process to expand the vasculature during embryonic development and adult life. In many
inflammation related diseases, the angiogenic neovasculature is a microanatomical feature of
medically important diseases, including cancer, atherosclerosis, and arthritis to name a few.
Neovascularization reflects a multitude of pathologic processes that include cytokine
liberation by inflammatory cells to stimulate endothelial proliferation, neovessel sprouting
and microvessel development, as well as the secretion of matrix dissolving enzymes, such as
metalloproteinases, elastases, and collagenases, that facilitate endothelial cells and tubule
penetration through the extracellular matrix in cancer and arthritis progression [68–70]. The
list of diseases that have angiogenesis as an underlying mechanism grows longer every year.
Although PAT generates high-resolution images of red blood cells in the microvasculature,
[71–77] hemoglobin imaging cannot discriminate immature neovasculature from mature
microvessels. Moreover, neovessel sprouting and bridging, which is a significant component
of the neovascular contrast signal typically lacks any blood flow and is otherwise invisible
to PA imaging. The αvβ3-integrin, a heterodimeric transmembrane glycoprotein,, is
expressed by nonpolarized neovasculular endothelial cells [78] as well as numerous other
cell types including macrophages [79], platelets [80], lymphocytes [81], smooth muscle cells
[82] and tumor cells [83, 84]. Fortunately, the steric constraint of GNB and other particles
exceeding 100nm diameter within the vasculature precludes significant interaction with
nonendothelial integrin-expressing cells and greatly enhances neovascular target specificity
[85].
To date, photoacoustic contrast agents targeting angiogenesis have been designed around
integrin-targeted indocyanine green (ICG)-fluorescent-peptide conjugates [33, 86–90] and
coupled to SWNT. Unfortunately small molecule agents easily diffuse from the neovascular
vasculature and can bind the numerous cell types expressing ανβ3 integrin. SWNT, although
interesting academically, pose challenges for clinical translation in terms of bioelimination
and long term safety. ανβ3 GNB1 was vascularly constrained and could not be detected
microscopically beyond neovasculature of the Matrigel™ plug. This observation was further
supported independently by other reports using copolymer and nanoemulsion particles. [85,
91]
αvβ3-targeted GNB1 (160 nm), as opposed to GNBS (90 nm) with a higher potential for
extravasation or GNBP (290 nm) which was expected to have a short circulatory half-life
due to its overall mass and size. αvβ3-targeted GNB1 was produced by microfluidization as
discussed before by incorporating an αvβ3-peptidomimetic antagonist. αvβ3-peptidomimetic
antagonist was conjugated to PEG2000-phosphatidylethanolamine (0.1 mole%, Kereos, Inc,
St. Louis, MO, USA). [92] This quinalone nonpeptide was developed by Lantheus Medical
Imaging (Billerica, MA, US patent 6,511,648 and related patents) and produced by Kereos,
Inc. The vitronectin antagonist was initially reported and characterized as the 111In-DOTA
conjugate RP478 and cyan 5.5 homologue TA145. [93] The specificity of the αvβ3-ligand
mirrors that of the anti αvβ3-LM609 antibody [94] (Chemicon International, Inc., Temecula,
CA) as assessed by staining and flow cytometry. The IC50 for αvβ5, α5β1, and GP IIbIIIa
was determined to be >10 µM (Lantheus Medical Imaging, unpublished data).
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Neovascular imaging was performed in vivo in a Matrigel™ plug model of angiogenesis.
Matrigel™ (750 µl) enriched with fibroblast growth factor-2 (500 nm/mL; Sigma Aldrich,
St. Louis, MO) and heparin (64 U/mL) was implanted subcutaneously along the flank of
mice. PAT imaging was performed prior to treatment and serially imaged over 5 hours post-
injection on days 16 and 17 post Matrigel™ implantation. (Figure 16) Animals were
randomly distributed into four groups and received: 1) αvβ3-gold nanobeacons (αvβ3-GNB1,
n = 6) αvβ3-nanobeacons without gold (αvβ3-NB) followed by αvβ3-GNB1 (competitive
blockage, n = 2) non-targeted gold nanobeacons (NT-GNB1, n = 3) or saline (n = 2).
For the first time, high spatial resolution noninvasive PAT imaging of angiogenesis was
demonstrated using a 10 MHz ultrasound receiver which clearly revealed the formation of
nascent neovessel tubules, sprouts and bridges much of which was still without blood flow.
αvβ3-GNB1 produced a 600% increase in signal in a Matrigel™ plug mouse model relative
to the inherent hemoglobin contrast pretreatment. Competitive inhibition of αvβ3-GNB1 with
αvβ3-NB (no gold) blocked contrast enhancement to pretreatment levels. Similar images in
the saline control animals showed no change in vascular anatomy over the same time course.
Indeed these images illustrate the genesis of neovasculature in the Matrigel™ plug model. A
similar effect was seen with saline treated animals. Nontargeted GNB passively accumulated
in the tortuous neovascularity, but provided low (less than half) contrast enhancement of the
targeted agent. PA signal changes in the Matrigel™ plug were monitored serially over 5
hours or more (Figure 7).
The Matrigel angiogenesis study was supported histologically using a FGF Matrigel
subcutaneous explant from FVB/N-TgN(TIE2LacZ)182Sato mice following injection (IV)
of αvβ3-targeted rhodamine labelled GNB-M nanoparticles. These transgenic mice carry a
beta-galactosidase reporter gene under the control of the murine Tek (Tie2) promoter. LacZ
is expressed specifically in vascular endothelial cells in embryonic and adult mice.
Microscopy definitively established that rhodamine-labeled αvβ3-GNB1 targeted specifically
to immature neovasculature expressing PECAM+ but not Tie-2− localized along the implant
periphery, but not to other peripheral microvasculature expressing PECAM+ and Tie-2+.
(Figure 17) This experiment demonstrated that αvβ3-GNB1 PA imaging sensitively and
specifically discriminated angiogenesis from the adjacent microvasculature.
3. Small molecule-based and other exogenous PA agents
3.1 NIR cyanine dyes for real-time sentinel lymph node imaging
As we discussed previously, identification of SLN is a critical component of breast cancer
staging and management. [95–97] Another approach to this issue was taken by Pan et. al.
[98] wwith the development of a sub 20 nm "soft" polymeric nanoparticle. (Figure 18) This
new agent was designed for rapid intraoperative administration with real time PA imaging.
The intraoperative approach helps to eliminate anatomic plane displacement, which can
complicate detection between the preoperative images and the patient repositioning in the
OR. Moreover, by establishing a rapid operative procedure, the surgeon can determine the
most direct approach to the node for resection minimizing potential secondary complications
of the axillary dissection. The obvious key to this procedure is rapid signal generation with
adequate intraoperative persistence.
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The synthesis used by Pan et al utilized a one pot rapid synthetic pathway in which
polysterene-b-poly(acrylic acid) (PS8-b-PAA400, Mnx103, 0.8-b-33.0, polydispersity index:
PDI = 1.18, 0.00033 mmol, 0.5 mole%) was mixed with a co-surfactant, sorbitan monoleate,
to restrict the particle diameter to 20 nm. A near infrared cyanine dye (ADS832WS, λex =
824 nm, 1.90 × 105 L mol−1 cm−1) was incorporated to act as a surrogate photoacoustic
payload in this proof of concept study as shown in Figure 18.
Particle characterization was performed through many analytic techniques including TEM,
AFM and DLS, which revealed the hydrodynamic particle diameter (Dav) to be 16 ± 2 nm
with a polydispersity of 0.021. The anhydrous particle diameter was (Dah = 12 ± 0.4 nm)
based on TEM images and presented a height of 15 ± 0.4 nm based on AFM images. Due to
the incorporation of the NIR dye, the particle had high fluorescence with confirmed
absorbencies at 750–860 nm. Additionally, these particles were found to possess long shelf-
life stability (~40 days at ambient temperatures). Loading efficiency of dye was
approximately 97%. Figure 18. Interestingly, the new particle also possessed theranostic
potential, incorporating fumagillin and providing a prolonged release with dissolution
testing in vitro.
Photoacoustic tomographic imaging of the new agent as a marker for axillary lymph nodes
was studied in rats. Intradermal injection of the nanoparticles showed that the PA signals via
maximum intensity projection (MAP) (Figure 20) produced a contrast enhancement of
~510% almost immediately. The signal enhancement was retained for 30 minutes at the
SLNs and within 110 minutes, was almost completely drained. Such results suggest that
these nanoparticles were delayed in transit within the lymph nodes but maintained their
structural integrity and migrated out of the lymph nodes into the circulation system, which
was attributed to their miniature size.
3.2 Copper as a contrast agent in PA imaging of sentinel lymph nodes
In an interesting study, Pan et. al [99] has demonstrated how copper could be utilized as an
exogenous PA contrast agents for the identification of SLNs. The synthesis followed a self-
assembly of Cu-neodecanoate complexes with polysorbates (sorbitan mono-9-octadecenoate
poly(oxy-1,2-ethanediyl)) which were encapsulated within a phospholipid outer layer. As
synthesized nanoparticles were subsequently purified by exhaustive dialysis to remove
unbound copper (Figure 21).
The copper-rich nanoparticles had a hydrodynamic diameter of 86 ± 0.6 nm (Dh) with low
polydispersity of 0.21 ± 0.02. Negative electrophoretic potential of −12 ± 07 mV indicated a
complete encapsulation of the copper-polysorbate core with the surfactant. Further
characterization of these nanoparticles was performed using TEM, AFM, SEM, and energy-
dispersive X-ray spectroscopy (EDX). (Figure 22)
Cu-particles exhibited a PA signal that was significantly stronger and greater (The PA signal
amplitude obtained from NanoCuN was ~650 mV compared to that of ~140 mV from blood)
at 680 nm. Also, NanoCuN particles exhibited a strong absorption in the NIR region
compared to a weak one displayed by hemoglobin. In vivo studies were conducted in rats as
previously described to image the sentinel lymph nodes via PA imaging. Figure 23 shows a
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baseline image of the rat before NanoCuN administration presented as a maximum intensity
projection (MIP) (Figure 23b). An image immediately after NanoCuN injection into the paw
was showed initial uptake by the SLN (Figure 23c) which continued to increase for 60
minutes (Figure 23d).
3.3 Porphysome nanovesicles for multimodal biophotonic contrast agents
Many attempts at creating nanoparticles with optically active inorganic molecules have been
studied, [100–103] but despite their drug loading efficiency and questions regarding long-
term safety, [104–107] they have not been translated into the clinic. Organic nanoparticles
have been shown to have more biocompatibility. [107] Based on these premises, Lovell et.
al [108] synthesized a supramolecular self-assembled porphysome using porphyrin-lipid
conjugates. Polyethylene glycol (PEG)-lipids were included to enhance in vivo
pharmacokinetic properties as shown in Figure 24. These particles were spherical about 100
nm in diameter as confirmed by TEM. With greater magnification, it was shown that the
porphysome structure contained two layers of higher-density material separated by 2 nm
gaps. The porphysome showed two distinct absorption peaks at 400 nm and 680 nm,
confirming the properties regarding the NIR nature of the particle. By inserting metal ions
into the structure, Lovell was able to demonstrate the shifts in optical density bands at 440
nm and 670 nm, which also suggested that these porphysomes retained availability for metal
chelation.
Porphysomes were tested for its photochemical properties by exposing them to laser
irradiation. Thermal energy was released, which was similar in efficacy to that of gold
nanorods. Photoacoustic amplitudes were atleast six fold (670 nm) higher for porphysomes
than methylene blue, which is often used in the clinic for SLN detection, as mentioned
earlier. The addition of detergent to the porphysome decreased the photoacoustic signal by
six-fold while it had no effect on the methylene blue, indicating the necessary self-
quenching nature of the porphysome to give off its PA signals (Figure 25a, b, c).
To further show that porphysomes could be used concurrently with photoacoustic
tomography, in vivo studies were implemented by injecting porphysomes intradermally in
rats. Figure 25d shows that the local lymphatic network was clearly visible and detectable
within 15 minutes post-injection. Porphysomes displayed very strong photoacoustic signals
affording distinct localization of the lymph node distinct from surroundings vessels. After 2
days, porphysomes accumulated within the tumor area and exhibited high fluorescence
emission due to receptor-mediated endocytosis or more likely splenic uptake by
macrophages which migrated to the inflammatory sites associated with the tumors, as is
common for many particles.
4. Conclusion and future of photoacoustic tomography
For most of the preclinical work, the instrumentation is now commercially available; where
as the majority of the work reported was conducted with laboratory-built robotic scanners.
Visual Sonics, Inc., a subsidiary of SonoSite, Inc. was the first company to commercialize
photoacoustics systems. They integrated photoacoustic capability into their existing Vevo
LAZR™ platform to enhance high-resolution ultrasound-derived images with the sensitivity
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of optical imaging. This system provides real-time, in vivo imaging of deep tissue within a
pebetration capability up to 1 cm. The integrated, 20Hz tunable laser can be operated within
680–970 nm and a resolution down to 45 µm caould be achieved. High optical contrast is co-
registered with high-resolution imaging and an advanced analysis software package
provided the ability to capture 2D and 3D images. Recently Endra Life Sciences launched
Nexus128, a preclinical small animal imaging scanner with multimodal capabilities of
photoacoustic imaging and computed tomography (CT). This system is the only
commercially available fully 3-D photoacoustic CT scanner. The system is capable of
generating fast, non-invasive quantification of physiological parameters such as tumor
vasculature without ionizing radiation. Using Endra's Nexus 128™, Dominique Van de
Sompel et al. demonstrated improving image quality by correcting temperature changes
during long scans in both phantom and tissue samples. [109] Seno Medical Instruments, Inc.
developed an Opto-acoustic system, which allows for the identification of tumors ~ 2 mm
and has demonstrated the ability to see submillimeter structures. Recently, Seno Medical has
licensed their technology to VisualSonics. TomoWave Loboratories, Inc., a Texas based
company is also working towards the commercialization of this technique. As described in
TomoWave website, their optoacoustic system LOUIS-3D™ consists of a Q-switched laser
Spectra-Wave, generating wavelength 1064 nm, 532 nm and tunable in the near-infrared
from 730 nm to 850 nm. Of note, the first PA scanners have been placed in clinics as
prototypes for augmenting ultrasound techniques, such as SLN dye injection guidance.
As discussed above, photoacoustics imaging has been demonstrated by several groups using
agents, e.g. organic dyes [110], gold nanoparticles [53–56], copper neodecanoate
nanoparticles [99], single-walled carbon nanotubes (SWNT) [40, 52] and others [98]. These
agents have shown definite potential for PA SLN mapping, imaging angiogenesis and
melanoma with a depth capability of several centimeter, satisfactory spatial resolution.
However, their use is not always out of questions. Organic dyes are extensively used in
clinics but they are rather small (<2 nm), and thus can easily be transported into the echelon
lymph nodes, causing a high possibility of producing false positives [111]. Often times they
cause skin staining that leads to irritation. Gold nanoparticles of different sizes and
morphologies are utilized widely, however, their optical properties are highly dependent on
expensive and complicated surface chemistries. Their clinical use is also discouraged by the
unpredictable high cost. Copper-based approach could potentially provide an innovative,
inexpensive, and commercially viable approach. Although these particles were synthesized
in a highly stable manner, copper is known to pose neurotoxicity [112]. SWNTs are
inexpensive but the safety of these materials is still an ongoing debate [113]. With the
constant advancement of PA technology, the future of this novel modality will also be
dictated by the evolution of safer and sensitive molecularly targeted contrast agents.
The clinical opportunities garnered from the usage of PAT with approved dyes such as
methylene blue are significant, and may be further improved with some of the preclinical
agents discussed which would afford more robust and effective PA imaging. Moreover, the
addition of physiological and targeted molecular imaging with PA alone and in concert with
the new preclinical agents offers a significant expansion of the diagnostic utility of
ultrasound, which remains one of the most cost effective and protable imaging modalities in
medicine today.
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Figure 1.
Different classes of photoacoustic contrast agents.
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Figure 2.
SEM images of (A) Ag nanocubes and (B) AuNCs. The inset shows the corresponding TEM
images of the same sample. (C) UV-vis spectra of the samples obtained by titrating Ag
nanocubes with different volumes of 0.1 mM HAuCl4 solution.
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Figure 3.
(A) The measured PA signal amplitude generated with and without AuNCs in rat blood at
several wavelengths. Noninvasive PA imaging of a rat's cerebral cortex, (B) before the
injection of AuNCs and (C) about 2 h after the final injection of nanocages, which is the
peak enhancement point. Reproduced with permission from (22), copyright 2007 American
Chemical Society.
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Figure 4.
PA images of the axillary region of a rat taken (A) before and (B) 28 min after the injection
of AuNCs. (C) The changes of PA signal amplitude as a function of the post-injection time.
After the injection, PA signals increased with time, which means gradual accumulations of
the nanocages. (D–F) Depth capability of SLN mapping with AuNCs. The PA images were
acquired after the injection of nanocages for: (D) 126 min with a total imaging depth of 10
mm by placing a layer of chicken breast tissue on the axillary region; (E) 165 min with a
total imaging depth of 21 mm by adding another layer of chicken breast tissue; and (F) 226
min with a total imaging depth of 33 mm by using three layers of chicken breast tissue. The
bars represent the optical absorption. BV, blood vessel. SLN, sentinel lymph node.
Reproduced with permission from (30), copyright 2009 American Chemical Society.
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Figure 5.
In vivo noninvasive PA time-course coronal MAP images of B16 melanomas using [Nle4,
D-Phe7]-a-MSH- and PEG-AuNCs. (A, E) a schematic of the [Nle4, D-Phe7]-a-MSH- and
PEG-AuNCs. Time-course PA images of the B16 melanomas after intravenous injection
with 100 µl of 10 nM (B–D) [Nle4, D-Phe7]-a-MSH- and (f–H) PEG-AuNCs through the tail
vein. the background vasculature images were obtained using the PA microscope at 570 nm
(ultrasonic frequency = 50 MHz), and the melanoma images were obtained using the PA
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macroscope at 778 nm (ultrasonic frequency = 10 MHz). reproduced with permission from
(31), copyright 2010 American Chemical Society.
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Figure 6.
(A) Increase of PA amplitude in the melanoma tumors after intravenous injection of [Nle4,
D-Phe7]-a-MSH- and PEG-AuNCs (n=4 mice for each group), respectively, for different
periods of time. The PA signals increased up to 38 ±6 % for [Nle4, D-Phe7]-a-MSH-AuNCs
while the maximum signal increase only reached 13 ± 2% for PEG-AuNCs at a post-
injection time of 6 h (p < 0.0001). (B) The average number of AuNCs accumulated in the
melanomas dissected at 6 h post injection for the two types of AuNCs as measured by ICP-
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MS. Here Ntumor denotes the number of AuNCs per unit tumor mass (g). Reproduced with
permission from (31), copyright 2010 American Chemical Society.
Pan et al. Page 28
Wiley Interdiscip Rev Nanomed Nanobiotechnol. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 7.
(A) Schematic of single-walled and multi-walled carbon nanotubes (SWNT and MWNT,
respectively). (B) Absorption spectra of SWNTs and golden carbon nanotubes (GNTs), and
photoacoustic (PA) spectra of GNTs. Lines represent normalized optical spectra (left
vertical axis) of GNTs in water (red curve), SWNTs in water (black curve) and water only
(green curve) and the dots represent normalized PA signal amplitude (blue dots, right axis)
of GNTs in water. The concentration of the SWNTs is ~35 times higher than that of GNTs;
hence 85- to 100-fold enhanced NIR contrast is achieved by the hybrid GNTs. Reproduced
with permission from Kim et. al. (36). (C) Optical absorption spectrum of SWNT-RGD
(black curve) and indocyanine green-enhanced SWNT-RDG (SWNT-ICG-RGD, green
curve). The optical absorbance spectrum of plain SWNT-RGD is relatively flat with slight
gradual absorption decrease as the wavelength increase. However, by attaching a large
number of ICG molecules to the SWNT surface, a 20-fold increase in optical absorption
results at 780 nm. Reproduced with permission from de la Zerda et. al. (34)
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Figure 8.
Single-walled carbon nanotube argine-glyice-aspartic acid (SWNT-RGD) tumor targeting in
living mice. Ultrasound (gray) and photoacoustic (PA) (green) images of a vertical slice
(white dotted line) through the tumors of mice injected with SWNT-RGD (right column)
and control plain SWNTs (left column). Subtraction images were calculated as 4 h post-
injection minus pre-injection to remove tissue background signal from the PA image. Mice
injected with SWNT-RGD showed an averaged 7-fold PA signal increase in the tumor over
mice injected with control untargeted SWNTs. The high PA signal in the mouse injected
with plain SWNTs (indicated by the white arrow) is not seen in the subtraction image,
suggesting that it is due to a large blood vessel and not SWNTs. Reproduced with
permission from de la Zerda et. al. (52)
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Figure 9.
Photoacoustic (PA) detection of single-walled carbon nanotube indocyanine green (SWNT-
ICG) in living mice. Vertical slices of ultrasound images (gray) and PA images (green) of
mice injected subcutaneously with SWNT-ICG-RGD at concentrations of 0.82–200 nm
(dotted black line). The white dotted lines on the images illustrate the approximate edges of
each inclusion. Quantitative analysis of the images estimated that 170 pm of SWNT-ICG-
RGD gives the equivalent PA signal as the tissue background. Reproduced with permission
from de la Zerda et. al. (34)
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Figure 10.
In vivo multiplex two-color photoacoustic (PA) detection of circulating tumor cells (CTCs).
(A) The 10 nm magnetic NPs (MNPs) coated with amphiphilic triblock polymers,
polyethylene glycol (PEG) and the amino-terminal fragment of urokinase plasminogen
activator (ATF). The 12 × 98 nm GNTs coated with PEG and folic acid. (B) PA spectra of ~
70µm veins in mouse ear (open circles). Absorption spectra of the MNPs and GNTs (dashed
curves) normalized to PA signals from CTC labeled with MNPs (black cricle) and GNTs
(open circle). (C) The size of the primary breast cancer xenografts at different time stages of
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tumor development. (D) Average rate of CTCs in mouse ear vein. Reproduced with
permission from Galanzha et. al. (35)
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Figure 11.
(A) Preparation of gold nanobeacons from octanethiol-functionalized gold nanoparticles
(AuNPs). x=1–2 mol% phospholipid coating. (B) TEM image of gold nanobeacons (drop
deposited over nickel grid, 1% uranyl acetate; scale bar: 100 nm). (C) AFM image of gold
nanobeacons. Average height Hav/nm=(10151) nm. (D) UV/Vis spectroscopic profile. Solid
blue line: gold nanobeacons; purple dashed line: octanethiol-coated AuNPs. Spectra are not
normalized. [Reproduced with permission from ref. 53]
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Figure 12.
(A) PA signals generated from a Tygon® tube (I.D. 250 µm, O.D. 500 µm) filled with GNB
and rat blood. The excitation light is of 764 nm wavelength. (B) PA spectrum of GNB and
blood over a 740–820 nm range of NIR wavelengths. (C) Ratio of the peak-to-peak PA
signal amplitudes generated from GNB to those of blood. (D) PA signal to noise ratio for the
GNB and the control (no gold). Cross-sectional PA image of a low density polyethylene
(LDPE) tube (~1cc volume, I.D. ~6 mm) filled with plasma clot: (E) control, (F) targeted
with GNB using a curved array PA system (λ = 800 nm). (G) Control, (H) targeted with
GNB using a photoacoustic breast scanner system (λ = 532 nm). [Reproduced with
permission from ref. 53]
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Figure 13.
(A) TEM image of gold nanorods drop deposited over Ni-grid; (B) TEM images of GNBR
drop deposited over Ni-grid; (C) AFM images of GNBR drop deposited over glass; (D) UV-
vis spectrum of gold nanorods showing LSPR and TSPR bands at 750 nm and 530 nm
respectively. [Reproduced with permission from ref. 55]
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Figure 14.
Top: Synthesis of GNBs. (Dav = Number averaged (DLS); ζ = electrophoretic (zeta)
potential; Hav = average height (AFM); PDI = polydispersity index (DLS)). Bottom: a
general scheme showing the effect of particle size in facile lymphatic distribution.
[Reproduced with permission from ref. 54]
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Figure 15.
In vivo noninvasive photoacoustic imaging of sentinel lymph nodes in rat (λ=767 nm). (A–
G) Scale bar is 5mm. 150 mL of nanobeacons were injected intradermally in all the cases.
GNB1: (A). Control PA image. (B) 5 min post-injection image of GNB1 (5 mM). GNBP:
(C). Control PA image. (D). Lymph node is not visible in a 60 min postinjection image of
GNBP (680 nM). GNBS: (E). Sagittal maximum amplitude projection (MAP) [67] pre-
injection control image: Bright parts represent optical absorption from blood vessels,
marked with red arrows. (F). PA image (MAP) acquired 5 min after GNBS injection (10
nM). SLNs are clearly visible, marked with green arrow. Lymphatic vessel is also visible,
marked with blue arrow. (G). 20 min post-injection PA image. [Reproduced with permission
from ref. 54]
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Figure 16.
0.75 mL of Matrigel™ was implanted subcutaneously in nude mouse. The mouse was
imaged photoacoustically 8–20 days after Matrigel™ implantation. (A) Photoacoustic (PA)
maximum amplitude projection (MAP) image of the dotted area. This is a control image.
After the control image was taken targeted gold nanobeacons (αvβ3-GNB-M) were injected
intravenously using the tail vein. In a time course study (B–K), PA images were acquired
with an interval of approximately 1/2 hour up to 5 h. (G) Three hour post-injection PA
image. Red arrows point to the angiogenic sprout (not visible in A). (K) Five hour post-
injection PA image. For all PA images λ = 767 nm, scale bar = 5 mm. (L) Digital
photograph of a mouse implanted with Matrigel™ plug. Blue arrow points to the plug. The
black dotted area was imaged. The smallest tick: 1 mm. (M) Digital photograph of the
sacrificed mouse after all the image acquisition was over. The skin was removed to show the
Matrigel™ plug (blue arrow). [Reproduced with permission from ref. 56]
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Figure 17.
Microscopic examination of FGF Matrigel subcutaneous explant from FVB/N-
TgN(TIE2LacZ)182Sato mice following injection (IV) of αvβ3-targeted rhodamine labelled
GNB-M nanoparticles. These transgenic mice carry a beta-galactosidase reporter gene under
the control of the murine Tek (Tie2) promoter. LacZ is expressed specifically in vascular
endothelial cells in embryonic and adult mice. (A) H&E staining of the excised implant
providing spatial orientation of the matrix with respect to skin and muscle. The red box
region is further examined in figures B, C and D. The blue box region is studied in more
detail in panels E, F, and G. Panels B and E depict the accumulation of αvβ3-targeted
rhodamine nanoparticles in the red and blue tissue regions respectively. Note the brilliant
and dense accumulation of NPs in panel B (red arrows) and little to no accumulation of
particles in the panel E. Region. Panels C and F depict the staining of vascular endothelium
for PECAM (CD34) in the red (C) and blue (F) regions of the matrigel plug. There was
dense vascularity in both locations (Red arrows in C and turquoise arrows in F. Panels D and
G depict the LacZ signal for betagalactosidase under Tie2 promoter control. In panel D, no
LacZ signal was appreciated, reflecting a paucity of mature microvessels. In
contradistinction, there is strong LacZ signal in panel G. These results indicated that the
αvβ3-GNB nanoparticles were specifically targeted to angiogenic endothelial cells (PECAM
+ /Tie-2 −) and not to more mature microvessels, which were PECAM +, Tie-2 +. The data
corroborated that PAT imaging with αvβ3-targeted GNB specifically distinguished and
enhanced the angiogenic neovasculature from new, but more matured and differentiated
microvessels. [Reproduced with permission from ref. 56]
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Figure 18.
Synthesis and characterization of theranostic polymeric micelles: i) co-self assembly of
amphiphilic diblock copolymer and sorbitan monooleate, ADS-832-WS (A) and/or
fumagillin (B), sonication, 25°C, 1 min; ii) dialysis 10 kDa cellulosic membrane, nanopure
water (0.2 µM). Reproduced with permission from Pan. et. al. (98)
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Figure 19.
a) TEM image of the polymeric micelles drop desposited over nickel brid, scale bar = 100
nm; b) AFM image of the micelles drop deposited over glass; c) physiochemical
characterization table for a NIR-polymer micelle; d) dissolution of ADS-832-WS from
micelle when incubated against rabbit plasma and human plasma albumin; (e) time-
dependent release of fumagillin from micelle. Reproduced with permission from Pan. et. al.
(98)
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Figure 20.
Non-invasive in vivo PA images of SLN in rat: For all PA images, the laser was tuned to
750 nm wavelength. a) Control PA image acquired before polymeric nanoparticle injection.
Bright parts represent optical absorption, here, from blood vessels (BV). b) PA image
(MAP) acquired immediately after the polymeric nanoparticle injection. c) 35 min post-
injection PA image. d) 110 min post-injection PA imageBlood vessel (BV), lymph vessel
(LV) and sentinel lymph node (SLN) are marked with arrows, and the SLN is visible in (b)–
(d), however, invisible in (a). e) Photograph of the rat after the hair was removed from the
scanning region before taking the PA images. The scanning region is marked with a black
dotted square. f) Photograph of the rat with the skin removed after PA imaging. g) Excised
lymph node. Smallest tick: 1 mm. h) PA signal enhancement in the SLN after the injection
of polymeric nanoparticle as a function of post-injection time. For (a)–(d): FOV = 25 mm ×
24 mm, step size along the X direction = 0.2 mm, step size along the Y direction = 0.4 mm,
total scan time = − 23 min. No signal averaging was used. Reproduced with permission from
Pan. et. al. (98)
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Figure 21.
Synthesis and physiochemical characterization of self-assembled nanoparticles of copper
neodecanoate. Schematic describing the preparation of copper-enriched nanoparticles: (i)
suspension of copper neodecanoate (1) in sorbitan sesquioleate, vigorously vortex and
mixing, filter using cotton bed, vortex; (ii) dissolve phospholipids in anhydrous chloroform
and preparation of phospholipid thin film by slow evaporation of solvent at 45°C under
reduced pressure; (iii) resuspension of the thin film in water (0.2 µM); (iv) self-assembly by
high pressure homogenization at 4°C, 20000 psi (141 MPa), 4 min; (v) dialysis (cellulosic
membrane, MWCO 20k); in box, characterization table for nanoparticles of copper
neodecanoate. Reproduced with permission from Pan et. al. (99)
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Figure 22.
Hydrodynamic particle size distribution from DLS; (b) UV-vis spectrum of NanoCuN
nanoparticles in water; (c) anhydrous state TEM image; (d,e) SEM images; (f) EDX
spectrum of the selected area from the image in (e); (g) AFM image (deposited on glass
substrate); shelf life stability of NanoCuN over 90 days from formulation; (i) dissolution of
Cu over 3 days when incubated with saline and human plasma albumin.
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Figure 23.
Noninvasive in vivo PA images (maximum intensity projections, MIP) of the SLN in a rat.
(a) Photograph of the rat with region of interest depilated before scanning. The scanning
region is delineated by a black dotted square. (b) Baseline PA image acquired before
NanoCuN injection. Bright regions represent inherent optical absorption from a blood vessel
(BV). (c) PA image (MIP) acquired almost immediately after NanoCuN administration. (d)
PA image 60 min post injection showing a marked signal enhancement corresponding to
increased NanoCuN uptake by the node: Blood vessel (BV) and sentinel lymph node (SLN)
are marked with arrows. The SLN is visible in both (c) and (d), however not apparent in (b).
(e) Photograph of the rat with the skin excised after PA imaging. For (b)–(d), FOV = 25 mm
× 24 mm, step size along the X direction = 0.2 mm, step size along the Y direction = 0.4
mm, total scan time = ~ 23 min. No signal averaging was used. Reproduced with permission
from Pan et. al. (99).
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Figure 24.
Porphysomes are optically active nanovesicles formed from porphyrin bilayers. a, Schematic
representation of a pyropheophorbide–lipid porphysome. The phospholipid headgroup (red)
and porphyrin (blue) are highlighted in the subunit (left) and assembled nanovesicle (right).
b, Electron micrographs of negatively stained porphysomes (5% PEG-lipid, 95%
pyropheophorbide-lipid). c, Absorbance of the porphyrin–lipid subunits incorporated in
porphysomes formed from pyropheophorbide (blue), zinc pyropheophorbide (orange) and
bacteriochlorophyll (red) in PBS. d, Resonance light scattering spectra ratio between gold
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nanorods and pyropheophorbide porphysomes. Nanorod and porphysome concentration was
adjusted to have equal optical density at 680 nm. e, Dynamic light scattering size profiles of
indicated porphysomes recorded in PBS. Reproduced with permission from Lovell et. al.
(109)
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Figure 25.
Multimodal optical utility of porphysomes. a, Photothermal transduction. Solutions were
irradiated with a 673nm laser and imaged with a thermal camera. b, Ratio of photoacoustic
amplitudes (P.A.) measured for porphysomes and methylene blue ±0.5% Triton X-100
(mean ± s.e.m. from 10 measurements). det., detergent. c, Photoacoustic images of tubing
containing porphysomes and PBS measured ±0.5% Triton X-100. d, Dual modality for
photoacoustic contrast and activatable fluorescence. Top, lymphatic mapping. Rats were
imaged using photoacoustic tomography before and after intradermal (i.d.) injection of
Pan et al. Page 49
Wiley Interdiscip Rev Nanomed Nanobiotechnol. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
porphysomes (2.3 pmol). Secondary lymph vessels (cyan), lymph node (red), inflowing
lymph vessel (yellow) and 5mm scale bar are indicated. Bottom, fluorescence activation
after i.v. injection of porphysomes (7.5 pmol) in a KB xenograft-bearing mouse.
Reproduced with permission from Lovell et. al. (109)
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